Stockreport

Praxis Precision granted Breakthrough Therapy designation for Ulixacaltamide [Yahoo! Finance]

Praxis Precision Medicines, Inc.  (PRAX) 
PDF ulixacaltamide, a differentiated and highly selective small molecule inhibitor of T-type calcium channels, for the treatment of patients with essential tremor Unlock h [Read more]